| Literature DB >> 25941577 |
Sarah K Maenhout1, Kris Thielemans1, Joeri L Aerts1.
Abstract
An increasing number of studies is focusing on the role of myeloid-derived suppressor cells (MDSCs) in the suppression of antitumor immune responses. Although the main site of action for MDSCs is most likely the tumor microenvironment, the study of these cells has been largely restricted to MDSCs derived from peripheral lymphoid organs. Only in a minority of studies MDSCs isolated from the tumor microenvironment have been characterized. This review will give an overview of the data available on the phenotypical and functional differences between tumor-derived MDSCs and MDSCs isolated from the spleen of tumor-bearing mice or from the peripheral blood of cancer patients.Entities:
Keywords: ATRA, all-trans retinoic acid; Bv8, Bombina variagata peptide 8; CTLA-4, cytotoxic T-lymphocyte antigen-4; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-γ, interferon gamma; IL, interleukin; IL-4Rα, interleukin-4 receptor alpha; LPS, lipopolysaccharide; M-CSF, macrophage-colony stimulating factor; MAPK, mitogen-activated protein kinases; MDSCs, myeloid-derived suppressor cells; NS cells, natural suppressor cells; PD-L1, programmed death-ligand 1; PHA, phytohemagglutinin; ROS, reactive oxygen species; TAMs, tumor-associated macrophages; Treg, regulatory T cells; VEGF, vascular endothelial growth factor.; iNOS, inducible nitric oxide synthase; immunosuppression; myeloid-derived suppressor cells; siRNA, small interfering ribonucleic acid; tumor immunology; tumor microenvironment; tumor models
Year: 2014 PMID： 25941577 PMCID： PMC4292540 DOI： 10.4161/21624011.2014.956579
Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110